Imminent Approval of Psilocybin In the last few years, we have seen a flurry of research activity and momentum building for psilocybin treatments to address unmet patient needs. We are starting to see innovation in application methodology, a steady stream of clinical...
The Increasing Trend of Drug Price Transparency There are presently nineteen states with drug price transparency laws, and an additional ten more states who have legislation pending. With disparate calculation and application, drug price transparency is beginning to...
Top 5 Mistakes Pharmacies Make During URAC Accreditation navigating clients through URAC accreditation, I’ve found the most problematic areas for pharmacies fall within a similar set of categories. Aside from these common challenges, URAC has adjusted their...
MDMA in Phase 3 Trials for FDA Approval Phase 3 trials are already underway for MDMA as treatment for PTSD. The effort is spearheaded by MAPS, who recently underwent organizational/leadership changes and a large fundraising campaign as they prepare to capitalize on...
NABP Accused of Enforcing ‘Shadow Regulation’ Twice in 3 years NABP is a private organization that mostly earns revenue by offering various services and software platforms to the Boards of Pharmacy, and accreditations and inspections to the drug and device supply...
